Horizon Pharma (NASDAQ:HZNP) rose 6.5% during trading on Monday after Cowen and company raised their price target on the stock from $15.00 to $17.00, Analyst Ratings Network reports. Horizon Pharma Inc. (NASDAQ:HZNP) shares after opening at $13.31 moved to $14.13 on last trade day and at the end of the day closed at $13.89. Company price to sales ratio in past twelve months was calculated as 16.51 and price to cash ratio as 15.30. Horizon Pharma Inc. (NASDAQ:HZNP) showed a positive weekly performance of 2.28%.
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, announced that it has been selected by American Pathology Partners (AP2) to provide its chromosomal microarray analysis (CMA) testing for miscarriage analysis to AP2 patients. American Pathology Partners is creating a nationwide network of leading anatomic pathology laboratories. CombiMatrix Corp (NASDAQ:CBMX) shares advanced 14.75% in last trading session and ended the day on $3.50. CombiMatrix Corp (NASDAQ:CBMX) return on equity ratio is recorded as -490.10% and its return on assets is -200.00%. CombiMatrix Corp (NASDAQ:CBMX) yearly performance is 9.72%.
On March 10, 2014, Julian C. Baker and Kelvin M. Neu, M.D. were elected to the Board of Directors (the “Board”) of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares moved up 6.32% in last trading session and was closed at $6.06, while trading in range of $5.73 – $6.10. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) year to date (YTD) performance is 30.89%.
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), on 27 February announced the appointment of Russell (“Russ”) Harrison to its board of directors, effective February 26, 2014. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) weekly performance is 26.15%. On last trading day company shares ended up $4.92. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) distance from 50-day simple moving average (SMA50) is 38.76%. Analysts mean target price for the company is $9.00.
Leave a Reply